BIOLASE, INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 12 rows in 2017. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2017-11-08: Reporting owner Lanman Richard B.; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2017-11-08: Reporting owner TALEVICH JAMES R; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2017-11-08: Reporting owner LORD JONATHAN T MD; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2017-11-01: Reporting owner Lanman Richard B.; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2017-11-08 | Lanman Richard B. Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +9,868 145,201 owned after | $0.57 exercise price | 2017-11-09 | |
| 2017-11-08 | TALEVICH JAMES R Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +9,868 454,638 owned after | $0.57 exercise price | 2017-11-09 | |
| 2017-11-08 | LORD JONATHAN T MD Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +19,737 578,131 owned after | $0.57 exercise price | 2017-11-09 | |
| 2017-11-01 | Lanman Richard B. Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +135,333 135,333 owned after | $0.76 exercise price | 2017-11-02 | |
| 2017-10-02 | BEAVER JOHN R Officer (SVP & Chief Financial Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +600,000 600,000 owned after | $0.59 exercise price | 2017-10-04 | |
| 2017-09-12 | LORD JONATHAN T MD Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +65,891 558,394 owned after | $0.61 exercise price | 2017-09-13 | |
| 2017-09-11 | LORD JONATHAN T MD Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +65,385 492,503 owned after | $0.54 exercise price | 2017-09-13 | |
| 2017-05-10 | CLARK PAUL N Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +203,345 754,221 owned after | $1.21 exercise price | 2017-05-12 | |
| 2017-05-10 | TALEVICH JAMES R Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +110,915 444,770 owned after | $1.21 exercise price | 2017-05-12 | |
| 2017-05-10 | MOLL FREDERIC H Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +105,634 456,623 owned after | $1.21 exercise price | 2017-05-12 | |
| 2017-05-10 | LORD JONATHAN T MD Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +105,634 427,118 owned after | $1.21 exercise price | 2017-05-12 | |
| 2017-03-27 | Nelson Mark Joseph Officer (SVP & Chief Financial Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +600,000 600,000 owned after | $1.28 exercise price | 2017-03-27 |